Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research
This article was originally published in The Pink Sheet Daily
Executive SummaryThe biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.
You may also be interested in...
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
Walgreens’ deal to acquire Alliance Boots vastly expands its international presence but got a chilly reception on Wall Street.